Skip to main content
. Author manuscript; available in PMC: 2010 Aug 23.
Published in final edited form as: Vaccine. 2008 Dec 16;27(7):1040–1049. doi: 10.1016/j.vaccine.2008.11.099

Fig. 5.

Fig. 5

Vaccination of mice with TA-CIN in GPI-0100 adjuvant completely protects against TC-1 tumor challenge. C57BL/6 mice (nine per group) were immunized with PBS, GPI-0100 alone, HPV16 L1 VLP (10 μg) in GPI-0100, TA-CIN (20 μg) alone, or TA-CIN with adjuvant GPI-0100 (50 μg) on days 0, 15, and 30. Seven days after the last vaccination the mice were challenged by subcutaneous injection of 5 × 104 TC-1 tumor cells/mouse. The mice were monitored for tumor growth by inspection and palpitation twice per week for 90 days. Tumor volume was measured starting from day 7 after tumor challenge and until euthanasia was required. A Kaplan–Meier survival analysis of mice challenged with TC-1 cells is shown.